nVerses Capital’s iRadimed IRMD Stock Holding History

nVerses Capital’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-400	Closed	-$17.6K	–	1198
2024 Q2	$17.6K	Buy	+400	New	+$17K	0.01%	821

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

nVerses Capital's IRMD Position: Q3 2024 in Review

nVerses Capital sold out of iRadimed (IRMD) in Q3 2024, closing a stake of 400 shares — an estimated $17.6K sold.

nVerses Capital first reported a position in IRMD in Q2 2024 and held it in 1 quarter. The position peaked at $17.6K in Q2 2024. 145 funds tracked by Wall St. Rank hold IRMD as of Q3 2024.

nVerses Capital reported no remaining iRadimed position as of Q3 2024 after selling out during the quarter.
nVerses Capital sold 400 iRadimed shares in Q3 2024, an estimated $17.6K.
nVerses Capital first reported a position in iRadimed in Q2 2024 and held it in 1 quarter.
nVerses Capital's iRadimed position peaked at $17.6K in Q2 2024.
145 funds tracked by Wall St. Rank held iRadimed as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.